keyword
MENU ▼
Read by QxMD icon Read
search

Elderly, chemotherapy, lung cancer

keyword
https://read.qxmd.com/read/30765643/-efficacy-and-safety-of-gefitinib-as-first-line-chemotherapy-for-elderly-patients-with-advanced-non-small-cell-lung-cancer-nsclc
#1
Kana Ohashi, Mikio Takamori, Yukiko Takahashi, Shoko Kawai, Miake Yamamoto, Miyako Kitazono, Kengo Murata, Akihiko Wada
Epidermalgrowth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is the first choice for the treatment of EGFR mutation- positive advanced non-small cell lung cancer(NSCLC). There have been few reports on the efficacy and safety of gefitinib in elderly patients with EGFR mutation-positive advanced NSCLC. We retrospectively assessed the efficacy and safety of gefitinib as first-line chemotherapy in 22 patients with advanced NSCLC aged 75 years or older and who were treated with gefitinib. The response rate was 81...
January 2019: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/30719055/investigation-on-advanced-non-small-cell-lung-cancer-among-elderly-patients-treated-with-chinese-herbal-medicine-versus-chemotherapy-a-pooled-analysis-of-individual-data
#2
Lingling Sun, Wan Sze Yim, Paul Fahey, Shutang Wang, Xiaoshu Zhu, Jing Qiao, Hezheng Lai, Lizhu Lin
Purpose: Many patients with advanced non-small-cell lung cancer (NSCLC) seek help from Chinese herbal medicine (CHM). The purpose of this study was to investigate the survival between CHM and chemotherapy (CT) treatment of patients aged ≥60 years with advanced Epidermal Growth Factor Receptor (EGFR) wild type NSCLC and Karnofsky Performance Status (KPS) ≥ 60. Methods: We extracted individual data of all eligible patients from 1 randomized control trial and 2 cohort studies and performed a pooled analysis...
2019: Evidence-based Complementary and Alternative Medicine: ECAM
https://read.qxmd.com/read/30692435/-a-case-of-an-elderly-patient-with-unresectable-her2-positive-gastric-cancer-successfully-treated-by-chemotherapy-combined-with-trastuzumab-over-a-long-period
#3
Yoshiro Yukawa, Atsushi Takeno, Kenji Kawai, Takuya Sakamoto, Junichi Inatome, Atsushi Naito, Kohei Murakami, Yoshiteru Katsura, Yoshiaki Ohmura, Yoshinori Kagawa, Toru Masuzawa, Chiyomi Egawa, Yutaka Takeda, Kohei Murata
An 82-year-old man was diagnosed with advanced gastric cancer(tub2, HER2-positive), and the clinical findings were T3N3M1(LYM), Stage Ⅳ. We started chemotherapy with capecitabine, cisplatin, and trastuzumab. After the first course, the dose of capecitabine was reduced and cisplatin was discontinued due to Grade 3 neutropenia. After 4 courses, the remarkable shrinking of the primary tumor and metastatic lymph nodes enabled us to assess the possibility of radical resection, but the patient and his family declined it because of his advanced age...
December 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/30692294/-a-very-elderly-patient-successfully-treated-by-multimodality-treatment-for-pancreas-cancer-with-synchronous-multiple-liver-metastases-and-liver-dysfunction
#4
Yasunori Hasuike, Ichiro Higuchi, Yoshihiro Mori, Sanae Hosomi, Akira Ishikawa, Yosuke Akiyama, Takahiko Tanigawa, Tatsuo Kitamura
We report an 86-year-old patient successfully treated by multimodality treatment for advanced pancreatic cancer with synchronous multiple liver metastases and liver dysfunction. Systemic chemotherapy(SC)(gemcitabine[GEM]1 g and 5-FU 1 g biweekly)was initiated. Two weeks after, the radiation therapy(55 Gy/25 days)was added. Three weeks after, the short period's high dose hepatic artery infusion(SPHDHAI)(5-FU[1 g]×3 days: 1 day rest: 5-FU[1 g]×3 days)was started. By these treatments, liver dysfunction was completely improved and abdominal pain was disappeared...
December 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/30653558/prospective-evaluation-of-the-g8-screening-tool-for-prognostication-of-survival-in-elderly-patients-with-lung-cancer-a-single-institution-study
#5
Yoko Agemi, Tsuneo Shimokawa, Jiichiro Sasaki, Kazuhito Miyazaki, Yuki Misumi, Akira Sato, Shinzi Aida, Mari Ishii, Yukiko Nakamura, Katsuhiko Naoki, Hiroaki Okamoto
The G8 questionnaire is a quick and easy-to-use screening tool. Several studies reported that the G8 questionnaire had a high sensitivity for predicting abnormalities in the full comprehensive geriatric assessment and predicted functional decline and survival in elderly cancer patients. The present study aimed to evaluate the role of the G8 questionnaire for predicting clinical outcomes and overall survival (OS) in elderly patients with lung cancer, who received chemotherapy or chemoradiotherapy. The data of 101 lung cancer patients aged ≥70 years, who were hospitalized between September 2011 and August 2014, were analyzed...
2019: PloS One
https://read.qxmd.com/read/30629215/congress-of-neurological-surgeons-systematic-review-and-evidence-based-guidelines-on-the-role-of-emerging-and-investigational-therapties-for-the-treatment-of-adults-with-metastatic-brain-tumors
#6
J Bradley Elder, Brian V Nahed, Mark E Linskey, Jeffrey J Olson
QUESTION: What evidence is available regarding emerging and investigational treatment options for metastatic brain tumors? TARGET POPULATION: Adult patients with brain metastases. RECOMMENDATIONS: <AbstractText Label="INTERSTITIAL MODALITIES" NlmCategory="UNASSIGNED">There is insufficient evidence to make a recommendation regarding the routine use of existing local therapies, such as interstitial chemotherapy, brachytherapy, or other local modalities, aside from their use in approved clinical trials...
March 1, 2019: Neurosurgery
https://read.qxmd.com/read/30600739/efficacy-and-safety-of-nanoparticle-albumin-bound-paclitaxel-in-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#7
Hong Tan, Jing Hu, Shan Liu
Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) offer more efficient paclitaxel delivery into tumor cells with fewer side effects than conventional chemotherapies. However, whether the efficacy of Nab-paclitaxel for non-small cell lung cancer (NSCLC) patients is age-related remains unknown. We performed this meta-analysis to evaluate the anticancer efficacy and safety of Nab-paclitaxel in NSCLC. Hazard ratios (HRs) or rate ratios (RRs) with corresponding 95% confidence intervals (CIs) for outcomes were retrieved...
January 2, 2019: Artificial Cells, Nanomedicine, and Biotechnology
https://read.qxmd.com/read/30572435/successful-treatment-with-temozolomide-in-an-elderly-woman-with-advanced-pulmonary-large-cell-neuroendocrine-carcinoma-a-case-report
#8
Juan Wei, Xiao Fang Dong, Zu Liang Hu, Sheng Tang, Yi Fang Lu
RATIONALE: Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare type of lung cancer, and 40% of patients are in stage IV at initial diagnosis. It has an extremely poor prognosis with a 1-year survival rate of 27%. Patients with LCNEC are predominantly male, older, and heavy smokers. There has been no clinical trial conducted to determine the best treatment for advanced LCNEC. Temozolomide (TMZ) has been successfully used to treat a variety of malignancies, such as glioblastoma multiforme, astrocytoma, non-small-cell lung carcinoma...
December 2018: Medicine (Baltimore)
https://read.qxmd.com/read/30557099/prophylaxis-of-chemotherapy-induced-neutropenia-and-febrile-neutropenia-with-lipegfilgrastim-in-2489-cancer-patients-final-results-from-the-non-interventional-study-nadir
#9
Thomas Fietz, Andreas Lück, Holger Schulz, Johanna Harde, Christoph Losem, Sina Grebhardt, Thomas Wolff, Karin Potthoff, Udo Müller, Matthias Zaiss, Christian Martin Kurbacher
OBJECTIVES: The non-interventional study (NIS) NADIR (DRKS00005711) evaluated the effectiveness and safety of prophylaxis with lipegfilgrastim, a glycopegylated granulocyte-colony stimulating factor, in 2500 patients undergoing chemotherapy in routine clinical practice. Primary objective was the incidence of chemotherapy-induced severe neutropenia, febrile neutropenia (FN) and neutropenia-associated complications. METHODS: NADIR was a prospective NIS conducted in 201 study centers in Germany...
December 17, 2018: Current Medical Research and Opinion
https://read.qxmd.com/read/30542036/-an-elderly-case-of-squamous-cell-lung-cancer-treated-continuously-with-pembrolizumab-without-any-decline-in-the-life-function
#10
Manami Sazuka, Yoko Murano, Kazufumi Takada, Keisuke Nonaka, Hirokazu Yamada, Hiroshi Yamamoto
BACKGROUND: Whether or not immune checkpoint inhibitors are safe and effective for the elderly remains unclear, even though these drugs were approved two years ago for the treatment of advanced non-small cell lung cancer in Japan. Older cancer patients are vulnerable to chemotherapy, so their life function should be closely monitored before starting, continuing, or discontinuing cancer treatment. CASE: An 85-year-old man showed a wedge-shaped shadow in the apical portion of the left lung on chest computed tomography...
2018: Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
https://read.qxmd.com/read/30527191/a-phase-ii-study-of-afatinib-treatment-for-elderly-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-harboring-egfr-mutations
#11
Hisao Imai, Kyoichi Kaira, Kensuke Suzuki, Masaki Anzai, Takeshi Tsuda, Tamotsu Ishizuka, Tomohito Kuwako, Ichiro Naruse, Kenji Nemoto, Junji Uchino, Nobutoshi Morozumi, Shinichi Ishihara, Koichi Minato, Takeshi Hisada
OBJECTIVE: The efficacy and safety of afatinib in elderly patients with EGFR-mutated non-small-cell lung cancer (NSCLC) have not been evaluated. This study aimed to assess the efficacy and safety of afatinib in elderly chemotherapy-naive patients with NSCLC harboring sensitive EGFR mutations. MATERIALS AND METHODS: We prospectively assessed the clinical effects of afatinib as a first-line treatment for elderly (age ≥70 years) NSCLC patients with EGFR mutations (exon 19 deletion or exon 21 L858R mutation)...
December 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30510426/short-and-long-term-outcomes-in-elderly-patients-with-locally-advanced-non-small-cell-lung-cancer-treated-using-video-assisted-thoracic-surgery-lobectomy
#12
Like Zhang
Background: In recent years, video-assisted thoracic surgery (VATS) lobectomy has been used to treat locally advanced non-small-cell lung cancer (LA-NSCLC). However, VATS has not been reported in elderly patients (≥70 years) with LA-NSCLC. The purpose of this study was to compare short- and long-term outcomes of patients with LA-NSCLC aged ≥70 years and 55-69 years treated with VATS. Patients and methods: From January 2012 to January 2018, a total of 83 patients with LA-NSCLC who were ≥55 years of age underwent VATS...
2018: Therapeutics and Clinical Risk Management
https://read.qxmd.com/read/30496584/phase-i-dose-escalation-study-of-pemetrexed-and-concurrent-thoracic-radiation-in-elderly-patients-with-non-squamous-non-small-cell-lung-cancer
#13
Kyoichi Kaira, Akihiro Ono, Yosuke Kamide, Noriaki Sunaga, Yasuhiko Koga, Jun-Ichi Saitoh, Katsuyuki Shirai, Takeshi Ebara, Takeshi Hisada, Tamotsu Ishizuka
The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose of pemetrexed with concurrent thoracic radiation therapy for elderly patients with previously untreated locally advanced non-squamous non-small-cell lung cancer (NSCLC). Pemetrexed was administered intravenously on Days 1, 22, 43, 64, 85 and 106. The initial doses of pemetrexed were planned as follows: Level 1 (400 mg/m2) and Level 2 (500 mg/m2). Concurrent thoracic radiation therapy was administered in 2-Gy fractions five times weekly, to a total of 60 Gy...
November 29, 2018: Journal of Radiation Research
https://read.qxmd.com/read/30467928/clinical-outcomes-of-carbon-ion-radiotherapy-for-locally-advanced-non-small-cell-lung-cancer
#14
Kazuhiko Hayashi, Naoyoshi Yamamoto, Mio Nakajima, Akihiro Nomoto, Hiroshi Tsuji, Kazuhiko Ogawa, Tadashi Kamada
Efficacy and safety of carbon-ion radiotherapy (CIRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) remain unclear. We reported the clinical outcomes of CIRT for LA-NSCLC. Data of 141 eligible patients who received CIRT between 1995 and 2015 were retrospectively analyzed. Local control (LC), locoregional control (LRC), progression-free survival (PFS), and OS were calculated using Kaplan-Meier method. The median age was 75.0 years. Overall, 21, (14.9%), 57 (40.4%), 43 (30.5%), and 20 (14.2%) patients had T1, T2, T3, and T4 disease, respectively...
November 22, 2018: Cancer Science
https://read.qxmd.com/read/30447689/hypothalamic-hypopituitarism-secondary-to-suprasellar-metastases-from-small-cell-lung-cancer-a-case-report-and-review-of-the-literature
#15
Ryohei Ono, Ryoji Ito, Keiko Nakagawa, Shinichi Teshima, Izumi Kitagawa, Hideyasu Sugimoto
BACKGROUND: Metastasis to the pituitary gland is an infrequent clinical problem, and the symptoms caused by metastases have been reported in only 2.5-18.2% of the cases. However, metastasis to the suprasellar lesion has rarely been reported in the literature. To the best of our knowledge, only nine cases of hypothalamic hypopituitarism due to metastases of solid tumors have been reported in English-language journals. CASE PRESENTATION: A 67-year-old Japanese man presented to our hospital with generalized weakness, lethargy, and weight loss...
November 18, 2018: Journal of Medical Case Reports
https://read.qxmd.com/read/30391573/compliance-and-outcome-of-elderly-patients-treated-in-the-concurrent-once-daily-versus-twice-daily-radiotherapy-convert-trial
#16
Marianna Christodoulou, Fiona Blackhall, Hitesh Mistry, Ahmet Leylek, Joost Knegjens, Vincent Remouchamps, Isabelle Martel-Lafay, Núria Farré, Matjaž Zwitter, Delphine Lerouge, Nicolas Pourel, Henri Janicot, Arnaud Scherpereel, Caroline Tissing-Tan, Karin Peignaux, Xavier Geets, Krzysztof Konopa, Corinne Faivre-Finn
INTRODUCTION: There is a lack of data on the efficacy and safety of concurrent chemoradiotherapy in elderly, limited-stage, patients with SCLC. METHODS: We compared outcomes of patients 70 years of age or older versus younger patients within the Concurrent Once-daily Versus twice-daily RadioTherapy (CONVERT) trial. Patients were randomized to receive 45 Gy/30 twice-daily fractions/19 days or 66 Gy/33 once-daily fractions/45 days concurrently with platinum-based chemotherapy...
October 31, 2018: Journal of Thoracic Oncology
https://read.qxmd.com/read/30368879/the-prognosis-analysis-of-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-targeted-treatment-combined-with-chemotherapy-in-smokers-with-non-small-cell-lung-cancer
#17
Biao Gu, Jipeng Wang, Yaqi Song, Qi Wang, Qingquan Wu
BACKGROUND: Administering epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) tyrosine kinase inhibitor (TKI) combined with chemotherapy in patients with non-small cell lung cancer (NSCLC) is a common treatment strategy. However, the prognostic factors for the EGFR-TKI combined with chemotherapy in smokers with NSCLC are still uncertain. PATIENTS AND METHODS: In this retrospective study, we enrolled patients with stage IV NSCLC diagnosed between June 2011 and March 2015 at two university-affiliated hospitals in China...
October 28, 2018: Journal of Cellular Biochemistry
https://read.qxmd.com/read/30349295/efficacy-and-safety-of-iodine-125-brachytherapy-combined-with-chemotherapy-in-the-treatment-of-advanced-nsclc-in-the-elderly
#18
Chunrong Wu, Bo Li, Guiyin Sun, Chunfang Peng, Debing Xiang
Background: Advanced non-small-cell lung cancer (NSCLC) is a huge challenge for physicians. Traditional chemoradiotherapy is associated with high rates of toxicities, especially when treating gerontal patients. Our study was focused on investigating the safety and efficacy of permanent iodine-125 seed implantation and chemotherapy for the treatment of advanced NSCLC in the elderly. Methods: Fifty elderly patients with stage III or IV NSCLC at our hospital from January 2011 to June 2017 were treated with the chemotherapy regimens (paclitaxel/cisplatin) and computed tomography (CT)-guided iodine-125 brachytherapy (group A), 50 patients who received chemotherapy consisting of paclitaxel and cisplatin only (group B) were matched-up with the patients in group A...
2018: OncoTargets and Therapy
https://read.qxmd.com/read/30334618/feasibility-of-early-multimodal-interventions-for-elderly-patients-with-advanced-pancreatic-and-non-small-cell-lung-cancer
#19
Tateaki Naito, Shuichi Mitsunaga, Satoru Miura, Noriatsu Tatematsu, Toshimi Inano, Takako Mouri, Tetsuya Tsuji, Takashi Higashiguchi, Akio Inui, Taro Okayama, Teiko Yamaguchi, Ayumu Morikawa, Naoharu Mori, Toshiaki Takahashi, Florian Strasser, Katsuhiro Omae, Keita Mori, Koichi Takayama
BACKGROUND: Combinations of exercise and nutritional interventions might improve the functional prognosis for cachectic cancer patients. However, high attrition and poor compliance with interventions limit their efficacy. We aimed to test the feasibility of the early induction of new multimodal interventions specific for elderly patients with advanced cancer Nutrition and Exercise Treatment for Advanced Cancer (NEXTAC) programme. METHODS: This was a multicentre prospective single-arm study...
October 18, 2018: Journal of Cachexia, Sarcopenia and Muscle
https://read.qxmd.com/read/30290823/identifying-patterns-of-care-for-elderly-patients-with-non-surgically-treated-stage-iii-non-small-cell-lung-cancer-an-analysis-of-the-national-cancer-database
#20
Eric D Miller, James L Fisher, Karl E Haglund, John C Grecula, Meng Xu-Welliver, Erin M Bertino, Kai He, Peter G Shields, David P Carbone, Terence M Williams, Gregory A Otterson, Jose G Bazan
BACKGROUND: To compare patterns of care for elderly patients versus non-elderly patients with non-surgically treated stage III non-small cell lung cancer (NSCLC) using the National Cancer Database (NCDB). We hypothesize that elderly patients are less likely to receive curative treatments, including concurrent chemoradiation (CCRT), compared to non-elderly patients. METHODS: We identified patients from the NCDB between 2003 and 2014 with non-surgically treated stage III NSCLC...
October 5, 2018: Radiation Oncology
keyword
keyword
109146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"